Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Literature DB >> 8297900

Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

N P Restifo¹, Y Kawakami, F Marincola, P Shamamian, A Taggarse, F Esquivel, S A Rosenberg.

Abstract

In this article, we explore the hypothesis that tumor cells can escape recognition by CD8+ T cells via deficiencies in antigen processing and presentation. Aspects of the molecular and cellular biology of major histocompatibility complex class I are reviewed. Evidence for histology-specific molecular mechanisms in the antigen-processing and -presentation deficiencies observed in some human and murine tumors is presented. Mechanisms identified include down-regulation of antigen processing, loss of functional beta 2-microglobulin, and deletion of specific alpha-chain alleles. Finally, we discuss studies using an antigen-presentation-deficient mouse tumor as a model for the immunogenetherapy of an antigen-presentation deficiency.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1993 PMID： 8297900 PMCID： PMC2555986 DOI： 10.1097/00002371-199310000-00004

Source DB: PubMed Journal: J Immunother Emphasis Tumor Immunol ISSN： 1067-5582

33 in total

Review 1. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes.

Authors: J W Yewdell; J R Bennink
Journal: Adv Immunol Date: 1992 Impact factor: 3.543

2. Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors: A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal: Nature Date: 1989-08-10 Impact factor: 49.962

3. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.

Authors: F Momburg; V Ortiz-Navarrete; J Neefjes; E Goulmy; Y van de Wal; H Spits; S J Powis; G W Butcher; J C Howard; P Walden
Journal: Nature Date: 1992-11-12 Impact factor: 49.962

4. Limit of T cell tolerance to self proteins by peptide presentation.

Authors: H Schild; O Rötzschke; H Kalbacher; H G Rammensee
Journal: Science Date: 1990-03-30 Impact factor: 47.728

5. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses.

Authors: G L Smith; J Z Levin; P Palese; B Moss
Journal: Virology Date: 1987-10 Impact factor: 3.616

6. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal: Science Date: 1991-12-13 Impact factor: 47.728

7. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.

Authors: A Porgador; R Bannerji; Y Watanabe; M Feldman; E Gilboa; L Eisenbach
Journal: J Immunol Date: 1993-02-15 Impact factor: 5.422

Review 8. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors: P D Greenberg
Journal: Adv Immunol Date: 1991 Impact factor: 3.543

9. Identification of human cancers deficient in antigen processing.

Authors: N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal: J Exp Med Date: 1993-02-01 Impact factor: 14.307

10. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Authors: N P Restifo; P J Spiess; S E Karp; J J Mulé; S A Rosenberg
Journal: J Exp Med Date: 1992-06-01 Impact factor: 14.307

26 in total

Review 1. Cancer vaccines: progress reveals new complexities.

Authors: Zhiya Yu; Nicholas P Restifo
Journal: J Clin Invest Date: 2002-08 Impact factor: 14.808

2. Characterization of gene expression profiles of T cells during anti-tumor response.

Authors: Christian Stremmel; Renate Siebenhaar; Roland Croner; Bertram Reingruber; Anthony J Slavin; Werner Hohenberger
Journal: Int J Colorectal Dis Date: 2005-04-06 Impact factor: 2.571

Review 3. Enhancing the recognition of tumour associated antigens.

Authors: N P Restifo; B R Minev; A S Taggarse; B J McFarland; M Wang; K R Irvine
Journal: Folia Biol (Praha) Date: 1994 Impact factor: 0.906

Review 4. Prospects for the therapeutic use of anticancer vaccines.

Authors: R S Chamberlain
Journal: Drugs Date: 1999-03 Impact factor: 9.546

5. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors: Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal: J Clin Invest Date: 2018-05-14 Impact factor: 14.808

Review 6. Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.

Authors: V Schirrmacher
Journal: J Cancer Res Clin Oncol Date: 1995 Impact factor: 4.553

7. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors: Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal: J Immunother Date: 2010-01 Impact factor: 4.456